Traws Pharma, Inc., a clinical-stage biopharmaceutical company focused on infectious diseases, advanced its lead drug candidates during the latest quarter despite regulatory setbacks such as the FDA hold on its TXM IND. The company secured capital to support ongoing Phase 2 trials of Ratutrelvir for COVID-19 and Tivoxavir Marboxil for influenza, while ramping up preclinical efforts against hantavirus. Traws operates within a highly competitive infectious disease therapeutics space where regulatory approval and clinical outcomes critically shape value creation. Its current liquidity position signals financial pressure underlying the importance of upcoming clinical milestones and continued funding.